Biomarkers of Parkinson's disease: Present and future

Metabolism: Clinical and Experimental

Volumn 64, Issue 3, 2015, Pages S40-S46

  Miller, Diane B ^a   O'Callaghan, James P ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Fluid biomarkers; Imaging; Transcranial sonography; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; DOPAMINE; ANTIPARKINSON AGENT; SNCA PROTEIN, HUMAN;

ARTICLE; BRAIN NERVE CELL; CLINICAL ASSESSMENT; DISEASE COURSE; DOPAMINERGIC NERVE CELL; FOLLOW UP; HUMAN; NEUROPATHOLOGY; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA PARS COMPACTA; THERAPY EFFECT; APOPTOSIS; BLOOD; DEFICIENCY; EARLY DIAGNOSIS; GENETICS; METABOLISM; MOTOR PERFORMANCE; NEUROIMAGING; ODOR; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; REM SLEEP; RISK FACTOR;

ALPHA-SYNUCLEIN; ANTIPARKINSON AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; DOPAMINE; EARLY DIAGNOSIS; HUMANS; MOTOR SKILLS; NEUROIMAGING; PARKINSON DISEASE; PARS COMPACTA; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SLEEP, REM; SMELL;

EID: 84920941588     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.10.030     Document Type: Article

References (58)

1. C.W. Olanow, and J.A. Obeso The significance of defining preclinical or prodromal Parkinson's disease 27 2012 666 669
2. S. Sharma, C.S. Moon, A. Khogali, A. Haidous, A. Chabenne, and C. Ojo Biomarkers in Parkinson's disease (recent update) Neurochem Int 63 2013 201 229
3. I. Ferrer, I. Lopez-Gonzalez, M. Carmona, E. Dalfo, A. Pujol, and A. Martinez Neurochemistry and the non-motor aspects of PD Neurobiol Dis 46 2012 508 526
4. M.M. Mielke, and W. Maetzler A 'bird's eye' view on the current status and potential benefits of blood biomarkers for Parkinson's disease Biomark Med 8 2014 225 227
5. D.D. Truong, R. Bhidayasiri, and E. Wolters Management of non-motor symptoms in advanced Parkinson disease J Neurol Sci 266 2008 216 228
6. D. Arkadir, H. Bergman, and S. Fahn Redundant dopaminergic activity may enable compensatory axonal sprouting in Parkinson disease Neurology 82 2014 1093 1098
7. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89 95
8. S.T. DeKosky, and K. Marek Looking backward to move forward: early detection of neurodegenerative disorders Science 302 2003 830 834
9. C. Scherzer Searching for biomarkers of Parkinson's disease Biomark Med 3 2009 113 114
10. S. Fahn, and Parkinson Study Group Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 252 Suppl. 4 2005 IV37 IV42
11. D. Berg, A.E. Lang, R.B. Postuma, W. Maetzler, G. Deuschl, and T. Gasser Chang the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities Lancet Neurol 12 2013 514 524
12. D. Berg, R.B. Postuma, B. Bloem, P. Chan, B. Dubois, and T. Gasser Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease Mov Disord 29 2014 454 462
13. R. Bhidayasiri, and H. Reichmann Different diagnostic criteria for Parkinson disease: what are the pitfalls? J Neural Transm 120 2013 619 625
14. A.J. Lees, J. Hardy, and T. Revesz Parkinson's disease Lancet 373 2009 2055 2066
15. A.Y. Deutch Parkinson's disease redefined Lancet Neurol 12 2013 422 423
16. E. Saracchi, S. Fermi, and L. Brighina Emerging candidate biomarkers for Parkinson's disease: a review 5 2014 27 34
17. M.G. Schlossmacher, and B. Mollenhauer Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials Biomark Med 4 2010 647 650
18. J.R. Streffer, I.D. Grachev, C. Fitzer-Attas, B. Gomez-Mancilla, B. Boroojerdi, and J. Bronzova Prerequisites to launch neuroprotective trials in Parkinson's disease: an industry perspective Mov Disord 27 2012 651 655
19. L. Parnetti, A. Castrioto, D. Chiasserini, E. Persicheti, N. Tambasco, and O. El-Agnaf Cerebrospinal fluid biomarkers in Parkinson disease Nat Rev Neurol 9 2013 131 140
20. H. Chen, E.A. Burton, G.W. Ross, X. Huang, R. Savica, and R.D. Abbott Research on the pre-motor symptoms of Parkinson's disease: clinical and etiological implications Environ Health Perspect 121 2013 1245 1252
21. D. Mohammadi The Harvard Biomarker Study's big plan Lancet Neurol 12 2013 739 740
22. G. Poste Bring on the biomarkers Nature 469 2011 156 157
23. K. Marek, D. Jennings, S. Lasch, A. Siderowf, C. Tanner, and T. Simjuni The Paarkinson Progression Marker Initiative (PPMI) Prog Neurobiol 95 2011 629 635
24. S.M. Rappaport Biomarkers intersect with the exposome 17 2012 483 489
25. K.D. Van Dijk, C.E. Teunissen, B. Drukarch, C.R. Jimenez, H.J. Groenewegen, and H.W. Berendse Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach Neurobiol Dis 39 2010 229 241
26. S. Yadav, A. Dixit, S. Agrawal, A. Singh, G. Srivastava, and A.K. Singh Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis Mol Neurobiol 46 2012 495 512
27. A. AIDakheel, L.V. Kalia, and A.E. Lang Pathogenesis-targeted, disease-modifying therapies in Parkinson disease Neurotherapeutics 11 2014 6 23
28. R.G. Hart, L.A. Pearce, B.M. Ravina, T.C. Yaltho, and J.R. Marler Neuroprotection trials in Parkinson's disease: systematic review Mov Disord 24 2009 647 654
29. A.E. Lang, E. Melamed, W. Poewe, and O. Rascol Trial designs used to study neuroprotective therapy in Parkinson's disease Mov Disord 28 2013 86 95
30. H. Alonso-Navarro, F.J. Jimenez-Jimenez, E. Garcia-Martin, and J.A. Agundez Genomic and pharmacogenomic biomarkers of Parkinson's disease Curr Drug Metab 15 2014 129 181
31. C. Klein, and A. Westenberger Genetics of Parkinson's disease Cold Spring Harb Perspect Med 2 2012 a008888
32. S.W. Scholz, T. Mhyre, H. Ressom, S. Shah, and H.J. Federoff Genomics and bioinformatics of Parkinson's disease Cold Spring Harb Perspect Med 2 2012 a009449
33. T. Gasser Genomic and proteomic biomarkers for Parkinson disease Neurology 72 Suppl. 2 2009 S27 S31
34. J. Nyhlen, R. Constantinescu, and H. Zetterberg Problems associated with fluid biomarkers for Parkinson's disease Biomark Med 4 2010 671 681
35. C.H. Adler, B.N. Dugger, M.L. Hinni, D.G. Lott, E. Driver-Dunckley, and J. Hidalgo Submandibular gland needle biopsy for the diagnosis of Parkinson disease Neurology 82 2014 858 864
36. M. Eller, and D.R. Williams α-Synuclein in Parkinson disease and other neurodegenerative disorders Clin Chem Lab Med 49 2011 403 408
37. E. Gelpi, J. Navarro-Otano, E. Tolosa, C. Gaig, Y. Compta, and M.J. Rey Multiple organ involvement by alpha-synuclein pathology in Lewy Body disorders Mov Disord 00 2013 1 9 10.1002/mds.25776
38. N.P. Visanji, C. Marras, L.N. Hazrati, L.N. Liu, L.W. Liu, and A.E. Lang Alimentary, my dear Watson? The challenges of enteric α- synuclein as a Parkinson's disease biomarker Mov Disord 29 2014 444 450
39. N. Wang, C.H. Gibbons, J. Lafo, and R. Freeman α-Synuclein in cutaneous autonomic nerves Neurology 81 2013 1604 1610
40. M. del Campo, B. Mollenhauer, A. Bertolotto, S. Engelborghs, H. Hampel, and A.H. Simonsen Recommendations to standarize preanalyticl confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update Biomark Med 6 2012 419 430
41. G.D. Mellick, P.A. Silburn, G.T. Sutherland, and G.A. Siebert Exploiting the potential of molecular profiling in Parkinson's disease: current practice and future probabilities Expert Rev Mol Diagn 10 2010 1035 1050
42. D. Berg, J. Godau, and U. Walter Transcranial sonography in movement disorders Lancet Neurol 7 2008 1044 1055
43. C. Gaig, and E. Tolosa When does Parkinson's disease begin? Mov Disord 24 Suppl. 2 2009 S656 S664
44. P.J. Tuite, S. Mangia, and S. Michaeli Magnetic resonance imaging (MRI) in Parkinson's disease J Alzheimers Dis Res S1 2013 001 10.4172/2161-0460.S1-001
45. W. Poewe, and P. Mahlknecht Combined assessment of midbrain hyperechogenicity, hyposmia and motor asymmetry improves diagnostic accuracy in early Parkinson's disease Expert Rev Neurother 12 2012 911 914
46. N. Shao, J. Yang, J. Li, H.F. Shang, G.W. Ross, and W. Poewe Voxelwise meta-analysis of gray matter anomalies in progressive supranuclear palsy and Parkinson's disease using anatomic likelihood estimation Front Hum Neurosci 8 2014 63 10.3389/fnhum.2014.00063
47. D. Berg, K. Marek, G.W. Ross, and W. Poewe Defining at-risk populations for Parkinson's disease: lessons from ongoing studies Mov Disord 27 2012 656 664
48. S. Lerche, M. Hobert, K. Brockmann, I. Wurster, A. Gaenslen, and S. Hasmann Mild parkinsonian signs in the elderly - is there an association with PD? Crossectional findings in 992 individuals PLoS ONE 9 2014 e92878
49. I. Liepelt-Scarfone, K. Gauss, W. Maetzler, K. Muller, and W. Fruhmann Berger Evaluation of progression markers in the premotor phase of Parkinson's disease: the progression markers in the premotor phase study Neuroepidemiology 41 2013 174 182
50. A.J. Noyce, J.P. Bestwick, L. Silveira-Moriyama, C.H. Hawkes, and J. Hardy PREDICT-PD: identifying risk of Parkinson's disease in the community: methods and baseline results J Neurol Neurosurg Psychiatry 2013 1 7
51. E. Garbayo, E. Ansorena, and M.J. Blanco-Preito Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems Maturitas 76 2013 272 278
52. A. Schneeberger, M. Mandler, F. Mattner, and W. Schmidt Vaccination for Parkinson's disease Parkinsonism Relat Disord 18 Suppl. 1 2012 S11 S13
53. E. Valera, and E. Masliah Immunotherapy for neurodegenerative diseases: focus on a-synucleinopathies Pharmacol Ther 138 2013 311 322
54. I. Devic, H. Hwang, J.S. Edgar, K. Izutsu, R. Presland, and C. Pan Salivary a-synuclein and DJ-1: potential biomarkers for Parkinson's disease Brain 134 2011 e178
55. M. Bogdanov, W.R. Matson, L. Wang, T. Matson, R. Saunders-Pullman, and S.S. Bressman Metabolomic profiling to develop blood biomarkers for Parkinson's disease Brain 131 2008 389 396
56. S.M. Rappaport, D.K. Barupal, D. Wishart, P. Vineis, and A. Scalbert The blood exposome and its role in discovering causes of disease Environ Health Perspect 2014 10.1289/ehp.1308015
57. K. Burgos, I. Malenica, R. Metpally, A. Courtright, B. Rakela, and T. Beach Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology PLoS ONE 9 2014 e94839
58. S.T. DeKosky, and S. Gandy Environmental exposures and the risk for Alzheimer disease JAMA Neurol 71 2014 273 275